January 2, 2023 — IBA, a world chief in particle accelerator know-how, at present confirmed that it has signed a contract with the Spanish Ministry of Well being to put in ten proton remedy programs throughout Spain as a part of a major public tender. This follows the announcement in August that IBA had certified as the one provider of the tender.
The whole worth of the contract to IBA is at the moment EUR 217 million, all taxes excluded, for the ten programs to be put in at 9 completely different websites in Spain. The contract doesn’t embody the everyday multi-year upkeep element which can be negotiated at a later stage. Income recognition will begin in 2022.
The mission is being funded by the Amancio Ortega Basis, which signed an settlement with the Spanish Ministry of Well being in 2021 beneath which the Basis agreed to donate funds for the acquisition of 10 proton remedy programs to be put in throughout Spain.
Olivier Legrain, Chief Govt Officer of IBA commented: “This important contract win for IBA is a testomony to the world-class high quality of our providing and validates our established standing because the proton remedy market chief with the distinctive capacity to answer a contract of such scale. We sit up for working carefully with the 9 facilities throughout Spain to ship this life-saving remedy to their sufferers.”
Luk Herremans, Govt Vice President of IBA Proton Remedy added: “Securing such a serious public tender underlines the rising significance of proton remedy within the remedy of most cancers, in a market that continues to see sturdy momentum globally with extra medical proof being generated on the remedy modality than ever earlier than. We welcome these new Spanish facilities to our IBA Campus neighborhood, which is the biggest on this planet and the place they may be capable to each be taught from and share with different members in an effort to present cutting-edge most cancers care to their sufferers.
For extra info: www.iba-worldwide.com
Associated Radioisotope Content material:
NorthStar Medical Radioisotopes Pronounces Provide Settlement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Provide Settlement for Therapeutic Radioisotope Actinium-225 (Ac-225)
Replace on HFR Reactor Outage – Medical Isotope Provide Returning to Regular
Replace on Unplanned Outage of the HFR Reactor
SNMMI Points Alert That HFR Outage Will Impression Isotope Provide
NorthStar Medical Radioisotopes Advances Concentrate on Therapeutic and Specialised SPECT Radiopharmaceuticals
How Nuclear Fusion is Revolutionizing Medical Isotope Manufacturing
FDA Approves Extra Molybdenum-99 (Mo-99) Filling Traces at NorthStar Medical Radioisotopes
Medical Isotope Business Opposes Export of Extremely Enriched Uranium for IRE
IBA and NorthStar Medical Radioisotopes Develop Collaboration to Allow World Availability of Tc-99m